There is evidence that IL-6 increases in NASH patients (Wieckowska et al., 2008) and STAT3 activation plays an important role in the fibrosis of NASH (Zhao et al., 2021). This evidence concerns the gene IL6 and metabolic dysfunction-associated steatohepatitis.